ADC Therapeutics SA (ADCT)
NYSE: ADCT · Real-Time Price · USD
1.370
+0.020 (1.48%)
Nov 18, 2026, 9:36 AM EST - Market open
ADC Therapeutics Revenue
ADC Therapeutics had revenue of $21.72M in the quarter ending September 30, 2026, with 32.20% growth. This brings the company's total for the last twelve months to $84.87M, up 12.85% year-over-year. In the year 2025, ADC Therapeutics had annual revenue of $81.36M with 14.85% growth. That makes ADC Therapeutics the 23,983rd largest company in the world by revenue and 3,405th in the United States.
Revenue (ttm)
$84.87M
Revenue Growth
+12.85%
P/S Ratio
2.24
Revenue / Employee
$439,756
Employees
193
Market Cap
192.71M
Revenue by Geography
- United States 73.55M 90.4%
- Europe, The Middle East and Africa 7.81M 9.6%
Fiscal year ended Dec 31, 2025 See the full ADC Therapeutics breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 81.36M | 10.52M | 14.85% |
| Dec 31, 2024 | 70.84M | 1.28M | 1.84% |
| Dec 31, 2023 | 69.56M | -140.35M | -66.86% |
| Dec 31, 2022 | 209.91M | 175.99M | 518.89% |
| Dec 31, 2021 | 33.92M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Organogenesis Holdings | 352.05M |
| Canopy Growth | 217.18M |
| Akebia Therapeutics | 197.20M |
| Glass House Brands | 176.98M |
| Anika Therapeutics | 123.43M |
| Lifecore Biomedical | 106.46M |
| Journey Medical | 69.52M |
| SIGA Technologies | 52.36M |
ADCT News
- 7 days ago - ADC Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 7 days ago - ADC Therapeutics registers to sell 61M common shares for holders - TheFly
- 8 days ago - ADC Therapeutics Registration statement: Registration filing - Filings
- 8 days ago - ADC Therapeutics Slides: Corporate presentation - Filings
- 9 days ago - ADC Therapeutics reports Q3 adjusted EPS (6c) vs. (19c) last year - TheFly
- 9 days ago - ADC Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Updates - PRNewsWire
- 9 days ago - ADC Therapeutics Earnings release: Q3 2026 - Filings
- 9 days ago - ADC Therapeutics Earnings release: Q3 2026 - Filings